Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks Roche reported positive topline results from its Phase II clinical trial, CT388-103, evaluating CT-388, Roches investigational dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist being developed for the treatment of obesity
doi: 10.1038/S41598-019-55524-W 116 O'NeilPMBirkenfeldALMcGowanBMosenzonOPedersenSDWhartonSet al
Thats the biggest change I finally feel like I can breathe between meals
Compared with the single components, the stack trades per-compound dose flexibility for convenience
US$ 26.81
US$ 24.66
US$ 29.52
US$ 29.59
